Mira Jung
About Mira Jung
Mira Jung, Ph.D., is a co‑founder of Shuttle Pharmaceuticals and has served as Chief Scientific Officer for Biology since December 2012; she previously served on the board from formation in December 2012 until 2019 . She is Professor of Radiation Medicine and Microbiology at Georgetown University Medical School (since 2004) with 30+ years of molecular radiation biology experience, 100+ publications, and nine USPTO patents; her work established HDAC inhibitor classes in modulating radiation response . Under her current 2023 employment agreement, she is engaged at approximately 20% time . Company performance context (EBITDA) over recent fiscal years is provided below.
| Metric | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|
| EBITDA ($USD) | -2,548,306* | -5,885,571* | -7,690,707* |
Values retrieved from S&P Global.*
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Shuttle Pharmaceuticals (SHPH) | Chief Scientific Officer for Biology | Dec 2012–present | Leads biology R&D; expertise in radiation resistance and HDAC inhibitors to enhance radiotherapy |
| Shuttle Pharmaceuticals (SHPH) | Director (Board member) | Dec 2012–2019 | Early governance contributor during company formation |
| Shuttle Pharmaceuticals (SHPH) | Co‑founder | Since formation | Co‑founded platform advancing radiation sensitizers/protectors |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Georgetown University Medical School | Professor of Radiation Medicine and Microbiology | 2004–present | NIH/DOD‑funded research; 100+ publications and nine patents; pioneering HDAC inhibitor research in radiation response |
Fixed Compensation
| Agreement Date | Base Salary | Time Commitment | Target Bonus | Notes |
|---|---|---|---|---|
| May 30, 2019 | $46,800 per year | Part‑time (approx. 8 hours/week per schedule) | $14,200 milestone‑based | Agreement included milestone‑based bonus; payroll/withholding terms disclosed |
| May 1, 2023 (replacing 2019 agreement) | $46,800 per year, representing ~20% time | ~20% | $15,620 milestone‑based | 2023 agreement updated salary/bonus targets and granted new RSUs |
Performance Compensation
Incentive Metrics and Bonus Structure
| Metric | Weighting | Target | Actual | Payout | Vesting/Timing |
|---|---|---|---|---|---|
| Milestone‑based bonus (operational/R&D milestones) | Not disclosed | $14,200 (2019) ; $15,620 (2023) | Not disclosed | Not disclosed | Annual, contingent on milestone achievement (specific metrics not enumerated) |
Equity Awards (RSUs, Options)
| Grant Type | Grant Date | Grant Size / Fair Value | Vesting Schedule | Status / Outstanding |
|---|---|---|---|---|
| RSUs (Initial under 2018 Plan) | May 30, 2019 | 892 RSUs (post‑reverse split basis) | Three equal annual installments on each 1‑year anniversary | Vested over 2019–2022 per schedule |
| RSUs (Additional grant under 2023 agreement) | May 1, 2023 | $20,200 worth of RSUs | Disclosed as annual one‑third increments commencing first anniversary ; footnote indicates two anniversary installments for the outstanding award table | 1,194 RSUs unvested at 12/31/2024; MV $1,026 |
| Stock Options | N/A | N/A | N/A | No option awards listed for Dr. Jung in FY 2024 outstanding awards table (option columns show “–”) |
Note: Later filings’ outstanding awards footnotes indicate the May 1, 2023 RSUs vest “in two installments on the anniversary of the grant date,” while the agreement narrative describes vesting in one‑third increments annually; we present both disclosures as filed .
Equity Ownership & Alignment
| Item | Detail |
|---|---|
| Unvested RSUs (as of 12/31/2024) | 1,194 units; market value $1,026 |
| Options (exercisable/unexercisable) | None listed for Dr. Jung in FY 2024 outstanding awards table |
| Stock ownership guidelines | Not disclosed in the extracted filings |
| Pledging/Hedging | No pledging/hedging disclosures found in the extracted sections; none indicated for Dr. Jung in the outstanding awards tables |
Employment Terms
| Term | Provision |
|---|---|
| Employment role & start | Chief Scientific Officer for Biology since Dec 2012 |
| Time commitment | ~20% under 2023 agreement |
| Severance (Good Reason) | 12 months of then‑applicable base salary, subject to compliance with agreement requirements |
| Change‑of‑control | Not specifically detailed in the extracted sections |
| Clawback | Not detailed in the extracted sections |
| Non‑compete / Non‑solicit | Not detailed in the extracted sections |
| Payroll/withholding | Company payments net of required withholding; paid per payroll practices |
Investment Implications
- Part‑time executive engagement (approx. 20%) suggests retention is structured around continued academic leadership while providing targeted domain expertise at SHPH .
- Compensation is predominantly low fixed cash with milestone‑based variable, and modest RSU grants; no option leverage is disclosed, indicating limited equity‑linked upside sensitivity for this role relative to typical biotech C‑suite packages .
- Upcoming anniversary‑based RSU vesting from the May 1, 2023 grant could create limited periodic selling pressure given 1,194 unvested units outstanding at FY 2024 and low market value, but the scale is small .
- Company‑level EBITDA has been negative across FY 2022–2024 (see table), underscoring a pre‑commercial profile; incentive alignment via milestone‑based bonus is tied to operational/R&D achievements rather than near‑term financial metrics .
Values retrieved from S&P Global.*